Receptor News and Research

RSS

Which GLP-1 meds have the most side effects? Study of 60,000 Facebook posts gives answers

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor agonist (GLP-1 RA) medications. Gastrointestinal symptoms were most common, while mental health concerns and tirzepatide-specific side effects were also flagged.

28 Jul 2025

Researchers discover new trigger for mitophagy

Autophagy is essentially the 'rubbish collection' of our cells. If there are problems in this process, which is so important for our health, diseases such as Parkinson's can result. In their latest study, leading cell biologists at the Max Perutz Labs at the University of Vienna investigated mitophagy - a form of autophagy - and came to a remarkable conclusion: the researchers have described a new trigger for mitophagy.

26 Jul 2025

Creatine may enhance neuroprotection through energy pathways

Creatine supplementation may improve cognitive performance and mood, offering insights into its role in muscle-brain interactions and overall health.

25 Jul 2025

Low-dose olanzapine reduces chemo-induced nausea with fewer side effects

Chemotherapy-induced nausea and vomiting are among the most distressing side effects of anti-cancer treatment, particularly for those receiving highly emetogenic regimens such as anthracycline plus cyclophosphamide combinations.

24 Jul 2025

Gut bacteria send direct signals to the brain to stop you from overeating

Researchers have discovered a novel gut-brain sensory circuit in mice where specialized colonic cells sense bacterial flagellin and rapidly suppress feeding via the vagus nerve. This "neurobiotic sense" operates independently of immune pathways, revealing a direct neural mechanism for microbiota-host communication.

24 Jul 2025

What happens to your weight after quitting GLP-1 anti-obesity drugs?

Stopping anti-obesity medications leads to significant weight regain, starting as early as eight weeks and stabilizing by six months. Despite this rebound, most patients maintain some weight loss compared to baseline a year after discontinuation.

23 Jul 2025

Research uncovers a 'neurobiotic sense' that lets the brain respond to gut microbe signals

In a breakthrough that reimagines the way the gut and brain communicate, researchers have uncovered what they call a "neurobiotic sense," a newly identified system that lets the brain respond in real time to signals from microbes living in our gut.

23 Jul 2025

New llama antibody-based treatment improves brain function in schizophrenia models

While current treatments for schizophrenia - a mental illness affecting 1% of the world's population - can reduce certain symptoms, they have little effect on the cognitive deficits affecting the daily life of patients.

23 Jul 2025

Chinese study shows lasting weight loss after tirzepatide treatment

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

23 Jul 2025

Powerlifting through breast cancer treatment shows new hope

LaShae Rolle, 27, is a competitive powerlifer who could squat 441 pounds, bench 292 pounds and deadlift 497 pounds. She is also a breast cancer survivor and researcher and the lead author on a first-of-its kind study documenting elite-level strength training during active breast cancer treatment.

23 Jul 2025

Temporary tattoo sticker could detect small amounts of GHB in alcoholic beverages

Temporary tattoos aren't just for kids anymore - semi-permanent versions have become a favorite among adults who don't want the commitment of the real thing.

23 Jul 2025

Can one drug do it all? Reviewing the expanding clinical universe of GLP-1 agonists

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide significant benefits for cardiovascular, kidney, liver, joint, and sleep-related diseases. These effects extend beyond weight loss, suggesting anti-inflammatory mechanisms with broad potential for managing chronic diseases.

22 Jul 2025

GLP-1 receptor agonists linked to lower dementia risk in type 2 diabetes

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for curbing dementia risk in people with the condition, finds the largest study of its kind, published in the open access journal BMJ Open Diabetes Research & Care.

22 Jul 2025

Date vinegar lowers blood sugar and cholesterol in type 2 diabetes

This study reveals that red date vinegar intake improves blood glucose and lipid profiles in type 2 diabetes, indicating potential for metabolic risk reduction.

22 Jul 2025

Weight regain observed in patients after ending obesity drug treatment

Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after halting their prescription, finds a meta-analysis published in BMC Medicine.

22 Jul 2025

Blocking a single gene disrupts vitamin D metabolism and cancer pathways in new cell study

Researchers identified SDR42E1 as a key regulator of vitamin D absorption and sterol metabolism in colorectal cancer cells. Disruption of this enzyme altered cancer-related pathways and cell viability, highlighting its potential as a therapeutic target.

21 Jul 2025